This study evaluates the clinical efficacy of #regorafenib in combination with #avelumab in mTLS-negative #SoftTissueSarcoma patients, highlighting the potential of #antiangiogenic agents to modify the #TumorMicroEnvironment. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

#NotchSignaling activation enhances #tumor angiogenesis in esophageal squamous-cell carcinoma (#ESCC) through the NOTCH1–USP5–STAT3 axis and targeting USP5 may offer a new avenue for #antiangiogenic therapies to improve ESCC treatment. #medsky

New in #STTT #OpenAccess: buff.ly/RYqLPpq

Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial Zhang et al. demonstrate that neoadjuvant anlotinib/sintilimab plus chemotherapy achieves 69% pathological complete response in triple-negative breast cancer, including PD-L1-negative patients, with 9...

#Medsky🧪 #oncosky #pharmasky Data suggest that PD-L1-negative patients with a cold triple-negative #breastcancer may benefit from the combination of #antiangiogenic therapy & #immunotherapy. @cellreports.bsky.social

www.cell.com/cell-reports...

PhD students of the lab presenting their work on #glioblastoma and #antiangiogenic immune checkpoint inhibition, at @kuleuvenuniversity.bsky.social #Oncoforum at Gasthuisberg.
Well done!

AI Predicts Kidney Cancer Drug Response Using Routine Pathology Slides Researchers at UT Southwestern developed an AI model that uses histopathological slide images to predict which kidney cancer patients will benefit from anti-angiogenic therapy. This deep learning mode...

AI Predicts Kidney Cancer Drug Response Using Routine Pathology Slides 🔬🧠📊 www.azoai.com/news/2025042... #KidneyCancer #AI #Medicine #CancerTreatment #PrecisionOncology #Pathology #Bioinformatics #AntiAngiogenic #Cancer #MedicalAI #DeepLearning